News | January 24, 2011

FDA Panel Recommends MRI Nervous System Imaging Agent

 gadobutrol

January 24, 2011 – A U.S. Food and Drug Administration’s (FDA) panel voted unanimously last week to recommend the clearance of a magnetic resonance imaging (MRI) contrast agent to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS). The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee said clinical trial and postmarketing data for a gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product. In addition to the vote for approval, committee members concurred in a 15-1 vote that gadobutrol should be labeled without an nephrogenic systemic fibrosis (NSF) contraindication in the at-risk population. NSF is a very rare but serious disease that affects a small percentage of patients with severe renal impairment who undergo contrast-enhanced MRI. All marketed GBCAs have a boxed warning about the potential for NSF in patients with chronic severe kidney disease or acute kidney injury. Gadobutrol is formulated at a 1.0 molar concentration (mol/L), which provides a higher concentration (lower volume) compared to other contrast agents used for CNS imaging. Bayer HealthCare Pharmaceuticals Inc. said it will continue to work with the FDA as it finalizes its review of gadobutrol. "Bayer is pleased that the advisory committee recognized the totality of the clinical and post-marketing data presented today," said Pamela A. Cyrus, M.D., vice president and head of U.S. medical affairs, Bayer HealthCare Pharmaceuticals. "If approved by the FDA, Bayer believes that gadobutrol will provide healthcare providers with an additional new option for CNS imaging in the United States." Data presented at the advisory committee meeting included results from two adequate and well-controlled phase 3 studies that confirmed the efficacy and safety of gadobutrol injection in contrast-enhanced MRI of the CNS. Prospectively defined primary and secondary endpoints were met in the two studies. The first phase 3 study compared the efficacy of combined gadobutrol-enhanced images plus unenhanced images to unenhanced images alone. The second phase 3 study used a crossover design with an active control, gadoteridol, to also compare the efficacy of the combined gadobutrol-enhanced plus unenhanced images to unenhanced images alone, as well as to confirm noninferiority of combined gadobutrol imaging versus combined gadoteridol imaging. The results of the first phase 3 study showed that gadobutrol-enhanced images compared to unenhanced images were superior in diagnostic performance and superior for the visualization variables, contrast enhancement, border delineation, and internal morphology. The results for comparison of unenhanced images compared to gadobutrol-enhanced images were consistent across both Phase 3 trials. In the second Phase 3 study comparing gadobutrol-enhanced images to images enhanced with the approved contrast agent gadoteridol, gadobutrol was confirmed to be non-inferior to gadoteridol with respect to visualization variables, contrast enhancement, border delineation and internal morphology, as well as the number of lesions detected. The most common adverse drug reactions observed in phase 2-4 trials for gadobutrol were generally consistent with those of other gadolinium based contrast agents. Across the studies (n=4,549), the most common adverse events associated with gadobutrol were: headache (1.5%), nausea (1.2%), injection site reactions (0.6%), dysgeusia (0.5%), feeling hot (0.5%), dizziness (0.4%), vomiting (0.4%), rash (0.3%), pruritis (0.2%), erythema (0.2%), dyspnea (0.2%), parasthesia (0.1%). During the entire clinical development program of gadobutrol, only isolated reports of serious adverse events were recorded. Overall, serious AEs (including fatal) were observed in 17 (0.4%) of 4,549 patients. One of the 17 serious AEs reported in the gadobutrol group was considered drug-related by the investigator (crystals in urine one day after injection). The New Drug Application (NDA) for gadobutrol was submitted to the FDA on May 14, 2010. The advisory committee's recommendations are not binding, but FDA reviewers will consider the panel's recommendation in its final assessment of the NDA. For more information: www.bayer.com

Related Content

Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Youth Football Changes Nerve Fibers in Brain

Statistically significant clusters (red-colored) showing group differences (Control vs. Football) in white matter strain along the primary (F1) and secondary (F2) fibers. While body of corpus callosum (BBC) showed relative shrinkage in Football group, the other clusters showed relative stretching of fibers. PCR: Posterior Corona Radiata, PLIC: Posterior Limb of Internal Capsule, SCR: Superior Corona Radiata, SLF: Superior Longitudinal Fasciculus, SCC: Splenium of Corpus Callosum. Image courtesy of Kim et al.

News | Neuro Imaging | December 07, 2018
Magnetic resonance imaging (MRI) scans show repetitive blows to the head result in brain changes among youth football...
Siemens Healthineers Debuts Magnetom Altea 1.5T MRI Scanner
Technology | Magnetic Resonance Imaging (MRI) | December 06, 2018
During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
Vital Showcases Enterprise Imaging Advances at RSNA 2018

Global Illumination from Vital Images

News | Enterprise Imaging | November 28, 2018
Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Arterys Demonstrates AI Cloud-Based Medical Image Analysis Solutions at RSNA 2018
News | Computer-Aided Detection Software | November 26, 2018
Medical imaging software company Arterys will demonstrate its wide-ranging suite of artificial intelligence (AI)-...